Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer

Biomaterials

Volumn 39, Issue , 2015, Pages 23-30

  Ahn, Jooyeon ^a   Miura, Yutaka ^b   Yamada, Naoki ^c   Chida, Tsukasa ^a   Liu, Xueying ^b   Kim, Ahram ^a   Sato, Ryuta ^d   Tsumura, Ryo ^d   Koga, Yoshikatsu ^d   Yasunaga, Masahiro ^d   Nishiyama, Nobuhiro ^c   Matsumura, Yasuhiro ^d   Cabral, Horacio ^a   Kataoka, Kazunori ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Drug delivery; Micelle; Nanoparticle; Platinum

Indexed keywords

ANTIBODIES; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; MICELLES; NANOPARTICLES; PLATINUM; TUMORS;

ANTIBODY FRAGMENT; ANTIBODY-DRUG CONJUGATES; CELLULAR INTERNALIZATION; EFFICIENT DRUG DELIVERY; PANCREATIC CANCERS; PANCREATIC TUMORS; POLYMERIC MICELLE; TUMOR TARGETED DELIVERY;

TARGETED DRUG DELIVERY;

ANTIBODY CONJUGATE; MALEIMIDE; NANOCARRIER; OXALIPLATIN; POLYMER; THROMBOPLASTIN; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FRAGMENT; MICELLE; NANOPARTICLE; PLATINUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MICELLE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; XENOGRAFT; ANIMAL; CHEMISTRY; CONFOCAL MICROSCOPY; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICELLES; MICROSCOPY, CONFOCAL; NANOPARTICLES; PANCREATIC NEOPLASMS; PLATINUM; POLYMERS;

EID: 84919482759     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.10.069     Document Type: Article

References (51)

1. Trail P. Antibody drug conjugates as cancer therapeutics. Antibodies 2013, 2:113-129.
2. Flygare J.A., Pillow T.H., Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013, 81:113-121.
3. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013, 12:329-332.
4. McDonagh C.F., Turcott E., Westendorf L., Webster J.B., Alley S.C., Kim K., et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006, 19:299-307.
5. Shen B.Q., Xu K., Liu L., Raab H., Bhakta S., Kenrick M., et al. Conjugation site modulates the invivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012, 30:184-189.
6. Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012, 30:631-637.
7. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M., Lenox J., Cerveny C.G., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10:7063-7070.
8. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784.
9. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26:925-932.
10. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68:9280-9290.
11. LoRusso P.M., Weiss D., Guardino E., Girish S., Sliwkowski M.X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011, 17:6437-6447.
12. Sievers E.L., Senter P.D. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013, 64:15-29.
13. Ducry L., Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010, 21:5-13.
14. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23:1137-1146.
15. Yokoyama M., Inoue S., Kataoka K., Yui N., Okano T., Sakurai Y. Molecular design for missile drug: synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier. Makromol Chem 1989, 190:2041-2054.
16. Aliabadi H.M., Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv 2006, 3:139-162.
17. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001, 47:113-131.
18. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006, 112:630-648.
19. Osada K., Christie R.J., Kataoka K. Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery. JR Soc Interface 2009, 6(Suppl.3):S325-S339.
20. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010, 624:25-37.
21. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
22. Gao Z., Lukyanov A.N., Chakilam A.R., Torchilin V.P. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. JDrug Target 2003, 11:87-92.
23. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 2003, 100:6039-6044.
24. Noh T., Kook Y.H., Park C., Youn H., Kim H., Oh E.T., et al. Block copolymer micelles conjugated with anti-EGFR antibody for targeted delivery of anticancer drug. JPolym Sci Pol Chem 2008, 46:7321-7331.
25. Li W., Zhao H., Qian W., Li H., Zhang L., Ye Z., et al. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 2012, 33:5349-5362.
26. Song H., He R., Wang K., Ruan J., Bao C., Li N., et al. Anti-HIF-1alpha antibody-conjugated pluronic triblock copolymers encapsulated with paclitaxel for tumor targeting therapy. Biomaterials 2010, 31:2302-2312.
27. Cabral H., Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. JControl Release 2014, 190:465-476.
28. Cabral H., Nishiyama N., Okazaki S., Koyama H., Kataoka K. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. JControl Release 2005, 101:223-232.
29. Murakami M., Cabral H., Matsumoto Y., Wu S., Kano M.R., Yamori T., et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med 2011, 3. 64ra2.
30. Nitori N., Ino Y., Nakanishi Y., Yamada T., Honda K., Yanagihara K., et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005, 11:2531-2539.
31. van den Berg Y.W., Osanto S., Reitsma P.H., Versteeg H.H. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012, 119:924-932.
32. Cole M., Bromberg M. Tissue factor as a novel target for treatment of breast cancer. Oncologist 2013, 18:14-18.
33. Lorenzet R., Napoleone E., Celi A., Pellegrini G., Di Santo A. Cell-cell interaction and tissue factor expression. Blood Coagul Fibrinolysis 1998, 9:S49-S59.
34. Saito Y., Hashimoto Y., Kuroda J-i, Yasunaga M., Koga Y., Takahashi A., et al. The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Eur J Cancer 2011, 47:2230-2239.
35. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6:815-823.
36. Kano M.R., Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A 2007, 104:3460-3465.
37. Miura Y., Takenaka T., Toh K., Wu S., Nishihara H., Kano M.R., et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 2013, 7:8583-8592.
38. Cabral H., Nishiyama N., Kataoka K. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. JControl Release 2007, 121:146-155.
39. Mochida Y., Cabral H., Miura Y., Albertini F., Fukushima S., Osada K., et al. Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor. ACS Nano 2014, 8:6724-6738.
40. Alley S.C., Benjamin D.R., Jeffrey S.C., Okeley N.M., Meyer D.L., Sanderson R.J., et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 2008, 19:759-765.
41. Erickson H.K., Park P.U., Widdison W.C., Kovtun Y.V., Garrett L.M., Hoffman K., et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006, 66:4426-4433.
42. Humphreys D.P., Heywood S.P., Henry A., Ait-Lhadj L., Antoniw P., Palframan R., et al. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel 2007, 20:227-234.
43. Song H.Y., Ngai M.H., Song Z.Y., MacAry P.A., Hobley J., Lear M.J. Practical synthesis of maleimides and coumarin-linked probes for protein and antibody labelling via reduction of native disulfides. JOrg Biomol Chem 2009, 7:3400-3406.
44. Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N., Watson G.J., et al. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability invivo. Cancer Res 1987, 47:5924-5931.
45. Barginear M.F., Budman D.R. Trastuzumab-DM1: a review of the novel immuno-conjugate for her2-overexpressing breast cancer. Open Breast Cancer J 2009, 1:25-30.
46. Chu T.W., Yang J., Kopecek J. Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis. Biomaterials 2012, 33:7174-7181.
47. Breij E.C., de Goeij B.E., Verploegen S., Schuurhuis D.H., Amirkhosravi A., Francis J., et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014, 74:1214-1226.
48. Sofuni A., Iijima H., Moriyasu F., Nakayama D., Shimizu M., Nakamura K., et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. JGastroenterol 2005, 40:518-525.
49. Kano M.R., Komuta Y., Iwata C., Oka M., Shirai Y-t, Morishita Y., et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci 2009, 100:173-180.
50. Dirisala A., Osada K., Chen Q., Tockary T.A., Machitani K., Osawa S., et al. Optimized rod length of polyplex micelles for maximizing transfection efficiency and their performance in systemic gene therapy against stroma-rich pancreatic tumors. Biomaterials 2014, 35:5359-5368.
51. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.